Increased Expression of Meteorin-Like Hormone in Type 2 Diabetes and Obesity and Its Association with Irisin.
METRNL
Meteorin-like hormone
adipomyokines
irisin
obesity
type 2 diabetes
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
19 10 2019
19 10 2019
Historique:
received:
24
08
2019
revised:
30
09
2019
accepted:
01
10
2019
entrez:
23
10
2019
pubmed:
23
10
2019
medline:
7
7
2020
Statut:
epublish
Résumé
Type 2 diabetes (T2D) is a growing pandemic associated with metabolic dysregulation and chronic inflammation. Meteorin-like hormone (METRNL) is an adipomyokine that is linked to T2D. Our objective was to evaluate the changes in METRNL levels in T2D and obesity and assess the association of METRNL levels with irisin. Overall, 228 Arab individuals were enrolled. Plasma levels of METRNL and irisin were assessed using immunoassay. Plasma levels of METRNL and irisin were significantly higher in T2D patients than in non-diabetic patients (
Identifiants
pubmed: 31635130
pii: cells8101283
doi: 10.3390/cells8101283
pmc: PMC6829873
pii:
doi:
Substances chimiques
Adipokines
0
FNDC5 protein, human
0
Fibronectins
0
Metrnl protein, human
0
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare that there is no potential conflicts of interest associated with this manuscript.
Références
Bone. 2015 Nov;80:115-125
pubmed: 26453501
Diabetes Care. 2008 Jan;31 Suppl 1:S55-60
pubmed: 18165338
IUBMB Life. 2016 Jul;68(7):544-56
pubmed: 27220658
Nature. 2012 Jan 11;481(7382):463-8
pubmed: 22237023
Genomics. 1999 Nov 15;62(1):98-102
pubmed: 10585775
Front Physiol. 2019 Jan 30;10:42
pubmed: 30761018
Cell. 2014 Jun 5;157(6):1279-91
pubmed: 24906147
Pathology. 2019 Feb;51(2):142-147
pubmed: 30612759
Diabetes Res Clin Pract. 2018 Jan;135:7-10
pubmed: 29097285
Acta Pharmacol Sin. 2016 May;37(5):571-9
pubmed: 27063217
Int J Endocrinol. 2013;2013:746281
pubmed: 24298283
J Diabetes. 2016 Jan;8(1):56-62
pubmed: 25494632
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jan;1864(1):37-50
pubmed: 29852279
Nat Genet. 2003 Jul;34(3):244-5
pubmed: 12833045
Cardiovasc Diabetol. 2017 Nov 9;16(1):147
pubmed: 29121940
Integr Med Res. 2014 Dec;3(4):155-160
pubmed: 28664092
Cell Metab. 2014 Jan 7;19(1):96-108
pubmed: 24411942
Diabetologia. 2014 Jun;57(6):1087-99
pubmed: 24676645
Int J Mol Sci. 2016 Dec 22;18(1):
pubmed: 28025491
Peptides. 2013 Jan;39:125-30
pubmed: 23219488
Lancet. 2017 Jun 3;389(10085):2239-2251
pubmed: 28190580
Int J Endocrinol. 2014;2014:857270
pubmed: 24864142
Adipocyte. 2012 Jul 1;1(3):164-167
pubmed: 23700527
J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78
pubmed: 23436919
Medicine (Baltimore). 2016 Jun;95(23):e3742
pubmed: 27281072
J Pharmacopuncture. 2017 Dec;20(4):235-242
pubmed: 30151293
Lipids Health Dis. 2012 Feb 23;11:30
pubmed: 22360800
Presse Med. 2013 May;42(5):839-48
pubmed: 23528336
Biochim Biophys Acta. 2015 Sep;1852(9):1867-75
pubmed: 26111885
Sci Rep. 2015 Jun 16;5:10949
pubmed: 26077345
Diabetes Res Clin Pract. 2018 Feb;136:100-107
pubmed: 29199003
Diabetes. 2014 Feb;63(2):514-25
pubmed: 24150604
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Adipocyte. 2014 Jan 1;3(1):67-8
pubmed: 24575373
Cell Physiol Biochem. 2015;37(6):2288-96
pubmed: 26625097
Sci Rep. 2016 Jul 19;6:29898
pubmed: 27432282
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
J Physiol. 2014 Mar 1;592(5):1091-107
pubmed: 24297848
Lipids Health Dis. 2016 Mar 11;15:54
pubmed: 26968837
Diabetologia. 2013 Jul;56(7):1638-48
pubmed: 23620060
Diabetes Res Clin Pract. 2013 Apr;100(1):96-101
pubmed: 23369227
Am J Physiol Endocrinol Metab. 2010 Aug;299(2):E145-61
pubmed: 20371735
J Endocrinol. 2010 Jan;204(1):1-11
pubmed: 19770178